February 12, 2020
STOCKHOLM, Feb. 12, 2020 /PRNewswire/ -- "2019 was the year when Alligator entered the clinical phase on a broad front. At the beginning of the year, we had one clinical project and at year-end, the number had increased to four", commented CEO Per Norlén. Significant events October -...
Source URL: https://www.prnewswire.com:443/news-releases/alligator-bioscience-ab-year-end-report-january-december-2019-301003507.html
|
